Penile neoplasm

Summary

Penile neoplasm (MONDO:0006895) is a cancer and 6 clinical trials. Top therapeutic interventions include dacomitinib anhydrous, nivolumab, and cabazitaxel. A subtype of penile disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	penile neoplasm
Mondo ID	MONDO:0006895
EFO	EFO:1001094
MeSH	D010412
DOID	DOID:11624
NCIT	C3317
SNOMED CT	126896003
UMLS	C0030849
MedGen	14656
MedDRA	10061913
Anatomy (UBERON)	UBERON:0000989
Is cancer (heuristic)	yes

Also known as: neoplasm of penis · neoplasm of the penis · penile neoplasm · penile neoplasms · penile tumor · penile tumour · penis neoplasm · penis neoplasm (disease) · penis tumor · penis tumour · tumor of penis · tumor of the penis · tumour of penis · tumour of the penis

Disease family

This is a subtype of penile disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › penile disorder › penile neoplasm

Related subtypes (6): erectile dysfunction, balanitis, leukoplakia of penis, phimosis, posthitis, vascular disorder of penis

Subtypes (3): penile cancer, Peyronie disease, benign neoplasm of penis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

7 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Cabazitaxel	Phase 2
Cisplatin	Phase 2
Dacomitinib Anhydrous	Phase 2
Ifosfamide	Phase 2
Nimotuzumab	Phase 2
Paclitaxel	Phase 2
Vinflunine	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT01728233	PHASE2	COMPLETED	Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis
NCT03012581	PHASE2	COMPLETED	Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT03114254	PHASE2	COMPLETED	A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
NCT03774901	PHASE2	UNKNOWN	Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
NCT05578820	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACOMITINIB ANHYDROUS	4	3
NIVOLUMAB	4	2
CABAZITAXEL	4	1
GANCICLOVIR	4	1